XBiotech (XBIT) Accounts Payables (2014 - 2026)
XBiotech (XBIT) posted quarterly Accounts Payables of $1.5 million for Q4 2025, down 30.95% year-over-year from $2.2 million in Q4 2024, and up 47.17% quarter-over-quarter from $1.0 million in Q3 2025.
XBiotech (XBIT) Accounts Payables (2014 - 2026) Analysis & Trends
XBiotech's Accounts Payables history runs 12 years deep, the most recent figure standing at $1.5 million for Q4 2025.
- In Q4 2025, Accounts Payables fell 30.95% year-over-year to $1.5 million; the TTM figure through Dec 2025 stood at $1.5 million (down 30.95% YoY), while the FY2025 annual figure was $1.5 million, down 30.95% from the prior year.
- Accounts Payables for Q4 2025 stood at $1.5 million, up from $1.0 million in the prior quarter.
- The five-year high for Accounts Payables was $2.6 million in Q1 2024, with the low at $1.0 million in Q3 2021.
- The 5-year median for Accounts Payables is $1.5 million (2021), against an average of $1.7 million.
- The sharpest annual moves came in 2021 and 2024: Accounts Payables plunged 78.08% in 2021, then jumped 92.11% in 2024.
- XBiotech's Accounts Payables stood at $2.1 million in 2021, then increased by 16.38% to $2.4 million in 2022, then grew by 4.49% to $2.5 million in 2023, then slipped by 11.65% to $2.2 million in 2024, then tumbled by 30.95% to $1.5 million in 2025.
- Business Quant data shows XBIT's Accounts Payables at $1.5 million in Q4 2025, $1.0 million in Q3 2025, and $1.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 108.02 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 428.93 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 35.57 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 622.65 Mn |
| 10 | XBiotech | 68.90 Mn | 68.90 Mn | - | 1.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.11 Mn |
| Dec 31, 2025 | 1.54 Mn |
| Sep 30, 2025 | 1.04 Mn |
| Jun 30, 2025 | 1.43 Mn |
| Mar 31, 2025 | 1.10 Mn |
| Dec 31, 2024 | 2.22 Mn |
| Sep 30, 2024 | 1.51 Mn |
| Jun 30, 2024 | 1.70 Mn |
| Mar 31, 2024 | 2.61 Mn |
| Dec 31, 2023 | 2.52 Mn |
| Sep 30, 2023 | 1.47 Mn |
| Jun 30, 2023 | 1.82 Mn |
| Mar 31, 2023 | 1.36 Mn |
| Dec 31, 2022 | 2.41 Mn |
| Sep 30, 2022 | 1.38 Mn |
| Jun 30, 2022 | 2.45 Mn |
| Mar 31, 2022 | 1.32 Mn |
| Dec 31, 2021 | 2.07 Mn |
| Sep 30, 2021 | 1.01 Mn |
| Jun 30, 2021 | 1.49 Mn |